Argenx stock holds after strong Q2 2026 sales growth
Published on 07/24/2026 at 08:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx (NL0010832176) stock is supported by a business that has already scaled quickly in 2026, with VYVGART sales and total revenue still doing the heavy lifting. The company reported Q1 2026 revenue of $776 million, up 78% year over year, and net product revenue of $756 million, up 78% from the same period a year earlier.
Revenue up 78%
That Q1 2026 revenue rise is the clearest current fundamental marker for Argenx. Net income also improved to $108 million in Q1 2026 from $20 million a year earlier, showing that growth is no longer just a top-line story.
Operating leverage matters as much as growth. Gross profit in Q1 2026 reached $740 million, while research and development spending was $371 million, both figures giving investors a better read on how much room the company has to fund its pipeline and commercial expansion.
Profit and spending
VYVGART remains the product to watch because it is still the main revenue driver. In the first quarter of 2026, product sales again accounted for the bulk of the company’s income, and that concentration means any change in demand will quickly show up in the next report.
The growth rate remains the key comparison point. Argenx posted $776 million of revenue in Q1 2026 versus $436 million in Q1 2025, a difference of $340 million that underlines how far the company has moved in one year.
VYVGART still drives
For investors, the question is no longer whether Argenx can generate meaningful sales. The more important issue is how long the current pace can last once the market starts comparing 2026 against a much larger base.
Market value matters
The latest market-cap and share-price figures were not available in the provided search call, so the report context stays centered on the company’s own latest disclosed numbers. Argenx shares trade on Euronext Amsterdam, and the stock framing remains tied to execution, margin discipline, and the next quarterly update.
Argenx at a glance
- Company: argenx SE
- ISIN: NL0010832176
- Ticker: EURONEXT: ARGX
- Trading venue: Euronext Amsterdam
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq 100
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
